Laboratory findings in patients treated with complement factor C3 inhibitor pegcetacoplanSaskia M C Langemeijeron January 2, 2026 at 11:00 am
Clin Chem Lab Med. 2026 Jan 5. doi: 10.1515/cclm-2025-1270. Online ahead of print. ABSTRACT OBJECTIVES: Complement inhibitor pegcetacoplan binds to C3 and its activation product C3b. Pegcetacoplan has been approved for the treatment of paroxysmal nocturnal hemoglobinuria. Because pegcetacoplan exerts broad inhibition of the complement cascade its efficacy is also investigated in numerous other diseases … Read more
